01—Abstract
Summary
Summary of the 8-K filed March 25, 2025. Cited figures are marked; the original filing is the authoritative source.
Illumina, Inc. (NASDAQ: ILMN) filed a Current Report on Form 8-K disclosing changes to its Board of Directors.
Stephen P. MacMillan notified the Board of his intention to resign as a director effective March 28, 2025, and the filing states his resignation is not the result of any dispute or disagreement with the Company. The Board elected Keith A.
Meister as a director beginning March 28, 2025. Mr. Meister will stand for election at the 2025 annual meeting of stockholders for a one-year term, and will participate in the non-employee director compensation programs described in the proxy statement filed on April 4, 2024. In a related Regulation FD disclosure, the Company stated that Dr. Scott Gottlieb has been elected non-executive Chair of the Board, effective March 28, 2025.
The accompanying press release (Exhibit 99.1) describes Dr. Gottlieb as a Board member since 2020 and Mr. Meister as founder, Managing Partner, and Chief Investment Officer of Corvex Management, who will bring experience as an investor in genomics. The release describes Mr. MacMillan as retiring from the Board in preparation for the upcoming annual shareholder meeting.
The filing contains no financial results or operating metrics. Its investor relevance lies in the leadership transition: a new independent Chair and a new director with an investor background, whose stated view is that Illumina has the right strategy to accelerate revenue growth and deliver shareholder value.
02—Key points
Key Highlights
- Stephen P. MacMillan resigned from the Board effective March 28, 2025, with the filing stating no dispute or disagreement with the Company.
- Keith A. Meister, founder and Chief Investment Officer of Corvex Management, joined the Board effective March 28, 2025, and will stand for election at the 2025 annual meeting.
- Dr. Scott Gottlieb was elected non-executive Chair of the Board, effective March 28, 2025.
- Dr. Gottlieb has served on the Board since 2020 and is a former FDA Commissioner (2017 to 2019), according to the press release.
- Mr. Meister will participate in the non-employee director compensation programs described in the April 4, 2024 proxy statement.
- The filing states there is no arrangement or understanding between Mr. Meister and any other person regarding his selection, and he has no reportable related-party transaction under Item 404(a).
- The Company furnished the press release under Item 7.01 (Regulation FD), which the filing states is not deemed filed for purposes of Section 18 of the Exchange Act.
03—Questions
Frequently Asked Questions
Who is leaving Illumina's Board?
Stephen P. MacMillan, who notified the Board of his intention to resign as a director effective March 28, 2025. The press release describes his departure as a retirement in preparation for the upcoming annual shareholder meeting.
Who is joining the Board and when?
Keith A. Meister was elected to the Board effective March 28, 2025. He will stand for election at the 2025 annual meeting of stockholders for a one-year term.
What leadership change was announced for the Board?
Dr. Scott Gottlieb was elected non-executive Chair of the Board, effective March 28, 2025.
Did the director resignation involve any disagreement with the Company?
No. The filing states that Mr. MacMillan's resignation is not the result of any dispute or disagreement with the Company or its Board on matters relating to operations, policies, or practices.
04—Continue